Effect of Hyoscine-N-Butyl Bromide on Hysterosalpingography-Associated Pain and Tubal Spasm. A Double-Blind Randomized Placebo-Controlled Study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202407618349397

Enrollment

136

Registered

2024-07-29

Start date

2024-03-11

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility-female

Interventions

Hyoscine Butyl Bromide

Placebo

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: All adult patients (female) = 18 years undergoing hysterosalpingography at the study centre during the study period and do not have any of the exclusion criteria

Exclusion criteria

Exclusion criteria: Non-consenting patients. Patients with active pelvic inflammatory disease Patients with a history of any allergy to radiopaque dye Patients with previous cervical surgery. Patients who took any form of analgesic within 6-hours before the procedure. Patients with congenital uterine abnormality or other indications for HSG aside from infertility. Patients with cardiac disease, e.g. cardiac failure, cardiac arrhythmias, hypertensive heart disease Patients with known allergies to hyoscine

Design outcomes

Primary

Measure	Time frame
Pain score;Tubal spasm	—

Secondary

Measure	Time frame
Incidence of side effects of hyoscine butyl bromide when used during HSG	—

Countries

Nigeria

Contacts

Public ContactEfena Efetie

Chief Consultant

efenae@yahoo.com+2348033118171

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026